Phase 3 Development and Current Evidence Level Retatrutide is in phase 3 development for several metabolic indications, including obesity and type 2 diabetes, while published phase 2 trials and 2026 phase 3 reports provide the main current human evidence [2], [7], [8]
This cost is similar to liraglutide, 3 mg daily, which costs about $1,050 per month
For example, one study from spring 2025 looked at the role of GLP-1 agonists (semaglutide, in this case) as a therapeutic for cardiometabolic disorders
If your vial is 5 mg/mL and you want 0.25 mg, you need to draw exactly 5 units (0.05 mL)
Roughly half of the participants received weekly semaglutide injections, while the rest were given a placebo for comparison
However, to date, no UK-specific national guideline exists that directly addresses switching from tirzepatide to semaglutide